Skip to main content

Benralizumab Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Aug 21, 2023.

Benralizumab is also known as: Fasenra

Benralizumab Pregnancy Warnings

In animal studies, there was no evidence of fetal harm with IV administration of this drug throughout pregnancy at doses that produced exposures up to approximately 310 times the exposure at the maximum recommended human dose (MRHD). There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

Caution is recommended.

AU TGA pregnancy category: B1
US FDA pregnancy category: Not assigned.

Risk Summary: Monoclonal antibodies such as this drug are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

-In women with poorly or moderately controlled asthma, there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and therapy adjusted to maintain optimal control.

See references

Benralizumab Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

-This drug is a humanized monoclonal antibody (IgG1/k-class), and immunoglobulin G (IgG) is present in human milk in small amounts.
-The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Product Information. Fasenra (benralizumab). Astra-Zeneca Pharmaceuticals. 2017.

References for breastfeeding information

  1. Product Information. Fasenra (benralizumab). Astra-Zeneca Pharmaceuticals. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.